Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy

Journal of Viral Hepatitis

Volumn 6, Issue 6, 1999, Pages 435-443

  Martinot Peignoux, M ^a   Roudot Thoraval, F ^b   Mendel, I ^c   Coste, J ^d   Izopet, J ^e   Duverlie, G ^f   Payan, C ^g   Pawlotsky, J M ^b   Defer, C ^h   Bogard, M ⁱ   Gerolami, V ^j   Halfon, P ^j   Buisson, Y ^k   Fouqueray, B ^l   Loiseau, P ^m   Lamoril, J ⁿ   Lefrere, J J ^o   Marcellin, P ^a   Le Breton, V ^a   Collin, C ^c   Buffet Janvresse, V ^c   Larrey, D ^p   Ducos, J ^p   Hahmane, S ^p   Castelan, S ^f   Khorsi, K ^f   Capron, D ^f   Lunel, F ^g   Oberti, D ^g   Bastie, A ^b   Dhumeaux, D ^b   Lucidarme, D ^q   Cayala, J M ^r   Barjonet, G ^r   Gatineau, G ^r   Glikmans, M ^r   Wartelle, C ^j   Grandadam, M ^k   Molinie C ^k   Niland, E ^k   Teysson, R ^k   Amiot, X ^l   Grange J D ^l   Bonnet, J ^m   Ravera, N ^m   Andant, C ⁿ   more..

^a BEAUJON HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d Laboratoire de Biologie Moléculaire   (France)

^e CHU PURPAN   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h ETS Nord Pas de Calais   (France)

ⁱ CENTRE HOSPITALIER DE MEAUX   (France)

^j HÔPITAL DE LA CONCEPTION   (France)

^k University of Paris Descartes   (France)

^l HÔPITAL TENON   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ HÔPITAL LOUIS MOURIER   (France)

^o HÔPITAL SAINT ANTOINE   (France)

^p HÔPITAL SAINT ELOI   (France)

^q Centre Hospitalier Saint Philibert GHICL   (France)

^r CHU Meaux   (France)

more..

Author keywords

Epidemiology; HCV genotypes; IFN therapy; Pathogenicity

Indexed keywords

INTERFERON;

ADULT; AGED; ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; FRANCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PRIORITY JOURNAL; VIRUS GENOME; VIRUS INFECTION;

ADULT; ANTIVIRAL AGENTS; FEMALE; FRANCE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032748876     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00187.x     Document Type: Article

References (44)

1. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute chronic non-A. non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
2. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 3382-3396.
3. Okamoto H, Kojima M, Okada S et al. Genetic drift of hepatitis C virus during 8.2 years of infection in a chimpanzee: variability and stability. Virology 1992; 190: 894-899.
4. Mizokami M, Gojobori T, Lau JY. Molecular evolutionary virology. Its applications to hepatitis C virus. Gastroenterology 1994; 107: 1181-1182.
5. Stuyver L, Van Arnheim W, Wyseur A, Hernandez F, Delaporte E, Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes. Proc Natl Acad Sci USA 1994; 91: 10134-10138.
6. Bukh J. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
7. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-583.
8. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology 1994; 19: 1321-1324.
9. Smith DB, Pathirana S, Davidson F et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997; 78: 321-328.
10. Alter HJ, Conry-Cantilena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997: 26 (suppl 1): 29S-33S.
11. Couroucé AM. Séroconversion anti-VHC chez les donneurs de sang. La Gazette de la Transfusion 1995; 114-115.
12. Dubois F, Descnclos JC, Mariotte N, Goudeau A and The Collaborative Study Group. Hepatitis C in a French population-based survey, seroprevalence, frequency of viremia, genotype distribution, and risk factors? Hepatology 1997; 25: 1490-1496.
13. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D and The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997; 26: 485-490.
14. Dusheiko G, Schmilovitzweiss H, Brown D et al. Hepatitis C virus genotypes: an investigation of type-specific difference in geographic origin and disease. Hepatology 1994; 19: 13-18.
15. Gournay J, Marcellin P, Martinot-Peignoux M et al. Hepatitis C virus genotypes in French blood donors. J Med Virol 1995; 45: 399-404.
16. Pawlotsky JM, Tsakaris L, Roudot-Thoraval F et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 1607-1016.
17. Nousbaum JB, Pol S, Nalpas B et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161-168.
18. Martinot-Peignoux M, Boyer N, Pouteau M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29: 214-232.
19. Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993; 31: 882-688.
20. Loiseau P, Stuyver L, Ravera N, Wolfe M, Benbunan C, Sayada C. HCV Amplicor-Lipa combined procedure: validation and benefit. Hepatology 1994; 20: 241A.
21. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
22. Lau JYN, Simmonds P, Urdea M. Implication of variations of 'conserved' regions of hepatitis C virus genome. Lancet 1995; 346: 425-426.
23. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc 1996; 71: 458-462.
24. Pol S, Thiers V, Nousbaum JB et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581-583.
25. Lau JYN, Davis GL, Prescott LE et al. and the Hepatitis Interventional Therapy Group. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996; 124: 868-876.
26. Mellor J. Homes EC, Jarvis LM, Yap PL, Simmonds P and the International HCV collaborative study group. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions; implications for virus classification. J Gen Virol 1995; 76: 2493-2507.
27. Tokita H, Okamoto H, Iizuka H et al. Hepatitis C variants from Jakarta Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996; 77: 293-301.
28. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25: 211-215.
29. Roffi L, Ricci A, Ogliari C et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29: 701-706.
30. Pozzato G, Kaneko S, Moretti M et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43: 291-296.
31. Tong MJ, El-Farra NS, Reikes A Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
32. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINVIR and DOSVIR groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
33. Cause X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
34. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-165.
35. Saracco G, Borghesio E, Mesina P et al. Prolonged treatment 92 years) with different doses (3 versus 6 MU) of interferon-α2b for chronic hepatitis C. Results of a multi-center randomized trial. J Hepatol 1997; 27: 56-62.
36. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995; 22: 1326.
37. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
38. Pawlotsky JM, Roudot-Thoraval F, Bastie A et al. Factors affecting treatment response to interferon alpha in chronic hepatitis C. J Infect Dis 1996; 174: 1-7.
39. Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 20 (suppl): 123S-127S.
40. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. Hepatitis C virus complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 1997; 25: 1251-1254.
41. Pawlotsky JM, Pellerin M, Bouvier MF et al. Genetic complexity of the hypervariable region I (HVR I) of hepatitis C virus: influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998; 54: 256-264.
42. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
43. Zein NN, Rakele J, Krawitt EL, Reddy R, Tominaga T, Persing DH, and the Collaborative Study Group. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity and response to interferon therapy. Ann Intern Med 1996; 125: 634-639.
44. Magrin S, Craxi A, Fabiano C et al. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily. J Hepatol 1996; 25: 583-590.